secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001104659-23-026064
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma upsizes buyback to $325M, cuts 17% staff, appoints new director
--------------------------------------------------------------------------------

- Capital return program increased to $325M; $170M remaining; $155M repurchased to date.
- Discontinuing research investments, reducing headcount by ~17%; inhaled JAK program to be partnered.
- Q4 2022 YUPELRI net sales $19.5M (TBPH implied 35% share), up 27% YoY; total revenue $14.6M.
- Appointed Susannah Gray to Board; William D. Young not standing for re-election; Board declassification proposal at May 2 AGM.
- 2023 guidance: R&D $35-45M, SG&A $45-55M; non-GAAP profit expected in 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/0001104659-23-026064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923026064/tm237863d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer